Your browser doesn't support javascript.
loading
The promising drugs included in WHO's Solidarity Project: a choice based in scientific knowledge and institutional competencies
Galina, Andréia Cristina; Sarzi, Deise; de Medeiros, Larissa Campos; Sampaio, André Luiz Franco; Leta, Jacqueline.
  • Galina, Andréia Cristina; Universidade Federal do Rio de Janeiro. Instituto de Bioquímica Médica Leopoldo de Meis. Programa de Educação, Gestão e Difusão em Biociências. Rio de Janeiro. BR
  • Sarzi, Deise; Universidade Federal do Rio de Janeiro. Instituto de Bioquímica Médica Leopoldo de Meis. Programa de Educação, Gestão e Difusão em Biociências. Rio de Janeiro. BR
  • de Medeiros, Larissa Campos; Instituto Nacional de Tecnologia. Divisão de Comunicação. Rio de Janeiro. BR
  • Sampaio, André Luiz Franco; Fundação Oswaldo Cruz-Fiocruz. Instituto de Tecnologia em Fármacos-Farmanguinhos. Departamento de Farmacologia. Rio de Janeiro. BR
  • Leta, Jacqueline; Universidade Federal do Rio de Janeiro. Instituto de Bioquímica Médica Leopoldo de Meis. Programa de Educação, Gestão e Difusão em Biociências. Rio de Janeiro. BR
Mem. Inst. Oswaldo Cruz ; 116: e200603, 2021. tab, graf
Article in English | LILACS | ID: biblio-1340225
ABSTRACT
BACKGROUND In March 2020, the World Health Organization (WHO) launched the Solidarity Program, probably the largest global initiative to encourage and support research in four promising drugs, named Remdesivir, Hydroxychloroquine, β Interferon and the combination Lopinavir / Ritonavir, to reduce the mortality of Coronavirus disease 2019 (COVID-19). OBJECTIVES Considering the potential impact of Solidarity Program to restrain the current pandemic, the present study aims to investigate whether it was designed upon indicators of scientific productivity, defined as the level of the production of new scientific knowledge and of the institutional capabilities, estimated in terms of scientific publications and technological agreements. METHODS The scientific documents on Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Coronavirus were retrieved from Scopus database while the technological agreements on coronavirus were obtained through Cortellis. As for the institutions and countries, we have considered the data on author's affiliations in both set of data. For comparison, we included the analysis of documents related with other drugs or therapies, such as vaccines and antibodies, which were listed in a Clarivate's report on coronaviruses research. FINDINGS Most of the analysis refers to documents on Coronavirus, the largest group. The number of documents related to WHO's drugs are almost five times higher than in the other groups. This subset of documents involves the largest and most diverse number of institutions and countries. As for agreements, we observed a smaller number of institutions involved in it, suggesting differences between countries in terms of technical and human capabilities to develop basic and/or clinical research on coronavirus and to develop new forms or products to treat or to prevent the disease. MAIN CONCLUSIONS Hence, the results shown in this study illustrate that decisions taken by an international scientific body, as WHO, were mainly based in scientific knowledge and institutional competencies.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Antiviral Agents / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Mem. Inst. Oswaldo Cruz Journal subject: Tropical Medicine / Parasitology Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Fundação Oswaldo Cruz-Fiocruz/BR / Instituto Nacional de Tecnologia/BR / Universidade Federal do Rio de Janeiro/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Antiviral Agents / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Mem. Inst. Oswaldo Cruz Journal subject: Tropical Medicine / Parasitology Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Fundação Oswaldo Cruz-Fiocruz/BR / Instituto Nacional de Tecnologia/BR / Universidade Federal do Rio de Janeiro/BR